ICCC
ImmuCell Corporation
ICCC trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over ICCC overall, supported by stronger modeled upside and stronger valuation.
ICCC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
ICCC's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICCC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $4.26 | -58% |
| Current | 54x | $10.22 | — |
| Fair | 83x | $15.70 | +54% |
| Expensive | 809x | $154 | +1403% |
Historical ranges are pointers, not guarantees.
ICCC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over ICCC in the historical PE scenario, which offers more potential upside but is not a forecast.
ICCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect ICCC's earnings and revenue to decline, with profitability weakening.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ICCC on the outlook, with more favorable earnings and revenue expectations.
ICCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.19 | -34% |
| Q2 2026 | $0.07 | -68% |
| Q1 2026 | -$0.07 | -$0.03 |
| Q4 2025 | -$0.12 | +$0.14 |
| Q3 2025 | $0.29 | +$0.79 |
| Q2 2025 | $0.22 | +$0.75 |
| Q1 2025 | -$0.04 | +$0.47 |
| Q4 2024 | -$0.26 | +$0.49 |
ICCC's earnings per share have fallen from their peak: $0.19 over the past year, against $0.29 in late 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ICCC on earnings, with more consistent year-over-year improvement.
ICCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8M | +46% |
| Q2 2026 | $7.2M | +12% |
| Q1 2026 | $10.4M | +28% |
| Q4 2025 | $7.6M | -1.6% |
| Q3 2025 | $5.5M | -8.4% |
| Q2 2025 | $6.4M | +18% |
| Q1 2025 | $8.1M | +11% |
| Q4 2024 | $7.8M | +52% |
ICCC's revenue is growing: $8M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +12 points |
| Q2 2026 | 27% | +18 points |
| Q1 2026 | 19% | +5.2 points |
| Q4 2025 | -0.8% | -8.8 points |
| Q3 2025 | 0.4% | +9.9 points |
| Q2 2025 | 8.8% | +34 points |
| Q1 2025 | 14% | +18 points |
| Q4 2024 | 8% | +28 points |
ICCC's operating margin was 12% last quarter, up 12 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ICCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ICCC on profitability, with a higher operating margin.
ICCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$589.4K | +$1.2M |
| Q2 2026 | $2.3M | +58% |
| Q1 2026 | $3.4M | +173% |
| Q4 2025 | $310.2K | +$509.5K |
| Q3 2025 | -$1.8M | -$1M |
| Q2 2025 | $1.4M | +207% |
| Q1 2025 | $1.2M | +258% |
| Q4 2024 | -$199.3K | +$605.1K |
ICCC has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ICCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +108K shares |
| 1 year | +2.8% | +252K shares |
| 3 years | +20% | +1.6M shares |
| 5 years | +19% | +1.5M shares |
| Available history | +36% | +2.5M shares |
ICCC has 9M diluted shares, up 2.8% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ICCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ICCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Very low |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 6.5x | High |
ICCC has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ICCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 34.9 | Neutral |
ICCC's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ICCC PE vs Healthcare Sector
| Metric | ICCC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 108% above |
| PE % | 36 | 29 | 7 pts above |
ICCC is trading at 54x earnings, a 108% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ICCC on valuation relative to its sector.
ICCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 1.2% above |
| 20 week MA | $10.3 | 0.8% below |
| 50 week MA | $8.54 | 20% above |
| 100 week MA | $7.15 | 43% above |
| 200 week MA | $6.02 | 70% above |
ICCC's trend is mixed: it's above four of its five weekly moving averages, and 70% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ICCC on trend strength, trading above more of its moving averages.
ICCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.90 | $6.25 | +28% |
| 2021 | $6.25 | $8.31 | +33% |
| 2022 | $8.31 | $6.23 | -25% |
| 2023 | $6.23 | $5.09 | -18% |
| 2024 | $5.09 | $4.98 | -2.2% |
| 2025 | $4.98 | $6.12 | +23% |
| 2026 YTD | $6.12 | $10.2 | +67% |
ICCC has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.